Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q3 FY24 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Feb 9, 2024
Slide 1: Cover letter to NSE: Investor Presentation
February 09, 2024 To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations a
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actua
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap Balaxi
Slide 5: Corporate Snapshot
Branded IPR-based pharma company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Supply Chain, Distribution, Transformation
Expansion initiated: Nicaragua, Ecuador, Chile (Latin America) 889 product registrations in six countries 700+ registrations submitted or in the pipeline Establishing the Company’s first Supply Chain pharmaceutical formulation facility in Hyderabad Successful process being replicated in other Distri
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep unders
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research ) Product Product Manufacturing ; Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from Asset Light’ to ‘Asset Rig
Slide 9: Investment in Manufacturing Facilities
ro ee Investment in Manufacturing Facilities Dots H se e eje e oe. 638 e e e e oe. 63° ee e e Setting up its first pharmaceutical formulation manufacturing unit a General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward in
Slide 10: Global Footprint
Global Footprint China @ Existing Market Dominican Republic India @ Targeted Expansion Guatemala 7 _ Central @ Product Sourcing Regions El Salvador African Republic Ecuador Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of § 6 billion
Slide 11: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 12: Group subsidiary structure
Balaxi Global DMCC, Balaxi Healthcare Dubai (WOS) Ecuador (WOS) Balaxi Balaxi Soon Balaxi Balaxi i Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African SRL (WOS) S.A (WOS) (WOS) (WOS) Republic(WOS Existing subsidiary com
Slide 13: Experienced Board of Directors
‘Experienced Board of Directors \ s Ashish Maheshwari /Minoshi Maheshwari /Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Bal
Slide 14: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS SEL EES eeeE Balaxi
Slide 16: Management's Comments
' Management’s Comments “During the quarter, we took various corrective measures to manage the exceptionally challenging situation that arose in the previous quarters due to unprecedented economic chaos in our oldest and biggest market of Angola, where local currency weakened in record time beyond t
Slide 17: Quarterly Financial Performance
Quarterly Financial Performance Particulars (INR Crore) Q3FY23 Revenue 86.58 33.85 Gross Margin % 39% EBITDA* 10.72 EBITDA Margin % 12.4% Profit After Tax* 8.22 PAT Margin % 9.5% Earnings Per Share (INR) 8.21 *During the current quarter, unrealised loss recognised in previous quarter profit and loss
Slide 18: Pharma Product Mix — Q3 FY24
Pharma Product Mix — Q3 FY24 Geographies Products a Africa* = Branded =u LATM** = Generics Dosage Forms Therapeutic Areas = Tablets = Antibiotics = Injectables = Analgesic = Liquids = Anti-malaria = Capsules Qa = Others = Others Balaxi *Africa: Angola and Central African Republic *LATM — Guatemala,
Slide 19: Historical Financial Performance (Consolidated): FY23
Historical Financial Performance (Consolidated): FY23 Particulars (INR Crore) FY22 Revenue 279.39 83.79 Gross Margin % 30.0% EBITDA 55.18 EBITDA Margin % 19.7% Profit After Tax 47.66 PAT Margin % 17.1% Earnings Per Share (INR) 47.66 NOTE: Financial Results for F¥23 are not strictly comparable with F
Slide 20: Pharma Product Mix — FY23
Pharma Product Mix — FY23 Geographies Products a Africa* = Branded a LATAM** = Generics Dosage Forms Therapeutic Areas g/.. a = Tablets a Antibiotics = Injectables = Analgesic = Liquids = Anti-malaria = Capsules = Others = Others Balaxi *Africa: Angola and Central African Republic *LATAM — Guatemala
Slide 21: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel hes Balaxi in 2020: Business Consolidation _ - = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-23: Expansion into New Geographies = Ai
Slide 22: Our Offerings / Thank You
Our Offerings ; " Anti-biotic j ‘a ig ’ Diuretic B i — } \ alax! ae analgesic — 7. geen Pharmaceuticals Limited Medical Device — yy A l Others Vitamins i ij - “@\ \ Anti-Emetic Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. ichodilator Telangana ocal Anesthe
Balaxi Pharmaceuticals — Q3 FY24 Earnings Presentation on 6ix